NCT00228397View on ClinicalTrials.gov

Study Evaluating CCI-779 in Relapsing Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

CCI-779

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00228397 - Study Evaluating CCI-779 in Relapsing Multiple Sclerosis | Biotech Hunter | Biotech Hunter